URGN - Latest News
UroGen Pharma Ltd. (URGN), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $1.51B. Beta to the broader market is 1.59.
The article list below shows the most recent URGN headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent URGN Headlines
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
globenewswire.com - May 15, 2026
PRINCETON, N. J.
UroGen Pharma Ltd. (URGN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
seekingalpha.com - May 13, 2026
UroGen Pharma Ltd.
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
globenewswire.com - May 13, 2026
64. 5% Probability of Remaining Event-Free at Three Years by Kaplan-Meier Analysis After Achieving Complete Response at Three Months First and Only FD
Urogen Pharma (URGN) Just Flashed Golden Cross Signal: Do You Buy?
zacks.com - May 11, 2026
From a technical perspective, Urogen Pharma (URGN) is looking like an interesting pick, as it just reached a key level of support. URGN's 50-day simp
UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027
seekingalpha.com - May 7, 2026
UroGen Pharma is reaffirmed as a Strong Buy, with a 12-month price target raised to $39/share, reflecting robust Q1 2026 results. Zusduri sales more
How News Affects URGN Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track URGN's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked URGN news questions
- What is the latest URGN news headline?
- The most recent URGN headline (May 15, 2026) is "UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the URGN news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What URGN news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual URGN options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.